CBD Stocks on the Rise

May 28, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com -- The marijuana industry has existed in the shadows for decades, generating tens of billions of dollars a year worldwide. But with the legalization of recreational marijuana in Canada, and the expected green light of adult-use weed from Mexico sometime later this year, cannabis is stepping out of the shadows and into a very profitable (and legitimate) scenario. One of the biggest opportunities in the market is CBD because it is already legal in the US.

Looking at opportunities in the CBD market for investors to start researching, Real Brands (USOTC: RLBD) jumps out. The company gives you all the benefit of the growing market without some of the risk producers face. RLBD is a branding company that is growing its portfolio of CBD brands by the day. The company has strong management with a solid background in branding and the beverage industry; and plans to expand their holdings focusing on at least three CBD categories: smokables, edibles and topical balms and lotions. The company recently updated their logo and brand identity. It is also developing an E-Commerce website and plans to launch it during the early part of the second quarter (which if you’re paying attention could be any day now) on their newly acquired domain name, to support online sales of a variety of smokable, edible, and topical CBD derived from hemp-based products for each of their brands.

The company continues to grow, RLBD just announced that we have signed a Letter of Intent with Integrative Medicine US, of Coral Springs, Florida, to acquire their proprietary CBD formulas consisting of Ancient Chinese Medicine and other Ancient Herbal Remedies that they have paired with the latest scientific breakthroughs in endocannabinoid systems, nutrients and CBD. Start your research today.

Today we are highlighting: Real Brands, Inc. (USOTC: RLBD), GW Pharmaceuticals plc (NASDAQ: GWPH), OrganiGram Holdings (OGI), Aphria Inc. (NYSE: APHA), and Hexo Corp (AMEX: HEXO).

Real Brands, Inc. (USOTC: RLBD) (Market Cap: $11.599M; Share Price: $0.077) is first and foremost a marketing and branding company, which has been slowly building its portfolio of trademarked brand names that could each represent on their own major partnerships and joint ventures going forward.

Jerry Pearring, the CEO of Real Brands commented, “As the demand for CBD infused products continues to grow, we intend to create marketing strategies in at least three CBD Categories: smokables, edibles and topical balms and lotions.”

Products like CBD gums are something which golfers Tiger Woods and Phil Mickelson are rumored to be chewing. The non-psychoactive health benefits of CBD are appealing for golfers.

That’s why RLBD announcing that PGA professional Scott Piercy is coming aboard as Brand Ambassador is big news. In March ‘19, he made a further commitment by making a long-term investment into Real Brands.

The audit on the horizon means this could also be another major event for investors to pay attention to. Start your research today.

________

OTHER CANNABIS COS TO RESEARCH INCLUDE:

GW Pharmaceuticals plc (NASDAQ: GWPH) (Market Cap: $5.64B; Share Price: $183.62), the world leader in the development and commercialization of cannabinoid prescription medicines, recently announced the appointment of Darren Cline as its new U.S. Chief Commercial Officer. Mr. Cline will lead the Epidiolex^® U.S. commercial organization and is expected to start on April 22, 2019.

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

________

OrganiGram Holdings (OGI) (Market Cap: $1.161B; Share Price: $7.49), a leading licensed producer of cannabis, announced that its common shares will commence trading on the Nasdaq Global Select Market under the symbol "OGI" on Tuesday May 21, 2019. Organigram's common shares will continue to be listed and trade on the Toronto Venture Exchange (TSXV), also under the symbol "OGI".

________

Aphria Inc. (NYSE: APHA) (Market Cap: $1.852B; Share Price: $7.35) shares fell after the Canadian cannabis company reported fiscal third-quarter results. It posted a C$108.2 million ($81.1 million) loss for its fiscal third quarter, or 43 cents a share, after a profit of C$12.9 million, or 8 cents a share, in the same period a year ago. Revenue climbed to C$73.6 million from C$10.3 million in the first full quarter of Canadian legal cannabis. But the company sold less cannabis than a year ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average retail selling price for medical cannabis increased to C$8.03 per gram from C$7.51, primarily because of higher oil sales.

In April, it announced that the previously announced take-over bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to meet the statutory minimum tender condition and has now expired and is terminated. As previously announced on April 15, 2019, the company entered into a definitive agreement with GGB to accelerate the expiry date of the Offer to April 25, 2019, as well as to terminate certain arrangements with GA Opportunities Corp. ("GAOC") for consideration of $89.0 million payable on future dates as set out in the April 15th press release. The Offer is now expired and terminated and no longer open to any Aphria shareholder to tender their shares. Accordingly, GGB will not be taking up any securities that may have been tendered to the Offer. GGB will promptly return to the securityholder any Aphria shares tendered and not withdrawn during the period from the commencement of the Offer up to the expiry time of the Offer.

________

HEXO Corp (AMEX: HEXO) (Market Cap: $1.429B; Share Price: $6.76) and Newstrike Brands Ltd. ("Newstrike") (TSX-V: HIP) had announced in March that they had entered into a definitive arrangement agreement (the "Arrangement Agreement") under which HEXO will acquire all of Newstrike’s issued and outstanding common shares in an all-share transaction valued at approximately $263 million. The Transaction gives HEXO the capacity to produce approximately 150,000 kg of high-quality cannabis annually. The Transaction also provides HEXO access to four cutting-edge production campuses totaling close to 1.8 million sq. ft. of near-term cultivation space and diversified growing and production techniques. This is in addition to HEXO’s 579,000 sq. ft. facility for a manufacturing and product development center of excellence in Belleville, Ontario. HEXO Corp has its headquarters in Gatineau Canada, and it produces and sells most of its cannabis products in the country.

The Brantford, Ontario-based Newstrike Brands were granted a cultivation license on 16 December 2016, and the company expects its harvest to be about 42,000 kg of cannabis. Although the company has not been around for long compared to HEXO, it has high capacity for cannabis production. HEXO recently announced that it had completed the first harvest in its 1 million sq. ft. expansion, marking an important execution milestone in the company's continuous growth.

HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. As one of the largest licensed cannabis companies in Canada, HEXO Corp operates with 1.8 million sq. ft of facilities in Ontario and Quebec and a foothold in Greece to establish a Eurozone processing, production and distribution center.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with RLBD dated 8/31/18. The agreement calls for $100,000 note issued to Regal Consulting, and 2,500,000 restricted 144 shares of RLBD for three months of service. Regal has elected to convert $73,000 of principal of the $100,000 note into 2,761,872 Restricted 144 shares of RLBD. Regal Consulting has agreed to a twelve- month term consulting agreement with RLBD dated 1/4/2019. The agreement calls for $10,000 in cash and 500,000 shares per month. All payments were made directly by Real Brands, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. RLBD was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: microcapspeculators.com

GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024